Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety

Chung, 2014, The role of the wearable cardioverter defibrillator in clinical practice, Cardiol. Clin., 32, 253, 10.1016/j.ccl.2013.11.002 Priori, 2015, 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs, Eur. Heart J., 36, 2757, 10.1093/eurheartj/ehv316 ZOLL Medical Corporation Chiarolla, 2019, Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Update 2018 Food and Drug Administration (FDA) Healy, 2015, Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: a cost-effectiveness evaluation, Heart Rhythm., 12, 1565, 10.1016/j.hrthm.2015.03.061 Ettinger, 2017, Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study, Med. Devices (Auckl), 10, 257 Maceira Rozas Masri, 2019, Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and Meta-analysis, JACC Clin. Electrophysiol., 5, 152, 10.1016/j.jacep.2018.11.011 Olgin, 2018, Wearable cardioverter-defibrillator after myocardial infarction, N. Engl. J. Med., 379, 1205, 10.1056/NEJMoa1800781 Mandrola Stecker, 2019, Wearable cardioverter–defibrillator after myocardial infarction, N. Engl. J. Med., 380, 599, 10.1056/NEJMc1816889 G. Goetz, B. Wernly, Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022. Decision Support Document 103/ 2. Update 2022.: 2022 [cited 24.10.2022]. Available from: https://eprints.aihta.at/1407/. Moher, 2010, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Int. J. Surg., 8, 336, 10.1016/j.ijsu.2010.02.007 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med., 6, 10.1371/journal.pmed.1000100 European Network for Health Technology Assessment (EUnetHTA) Aidelsburger, 2020, Effectiveness, efficacy, and safety of wearable cardioverter-defibrillators in the treatment of sudden cardiac arrest – results from a health technology assessment, Int. J. Technol. Assess. Health Care, 36, 363, 10.1017/S0266462320000379 Guyatt, 2011, GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J. Clin. Epidemiol., 64, 383, 10.1016/j.jclinepi.2010.04.026 Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, Bmj., 366, l4898, 10.1136/bmj.l4898 Sterne, 2016, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, Bmj., 355, i4919, 10.1136/bmj.i4919 Institute of Health Economics (IHE) Olgin, 2020, Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses, J. Cardiovasc. Electrophysiol., 31, 1009, 10.1111/jce.14404 Burch, 2021, Increased quality of life among newly diagnosed patients with heart failure with reduced ejection fraction in the months after initiation of guideline-directed medical therapy and wearable cardioverter defibrillator prescription, J. Cardiovasc. Nurs., 36, 589, 10.1097/JCN.0000000000000864 Daimee, 2018, Experience with the wearable cardioverter-defibrillator in older patients: results from the prospective registry of patients using the wearable cardioverter-defibrillator, Heart Rhythm., 15, 1379, 10.1016/j.hrthm.2018.04.014 Erath, 2018, Usefulness of the WCD in patients with suspected tachymyopathy, Clin. Res. Cardiol., 107, 70, 10.1007/s00392-017-1159-1 Erath, 2017, The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients, Clin. Res. Cardiol., 106, 300, 10.1007/s00392-016-1054-1 Garcia, 2021, Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study, Europace., 23, 73, 10.1093/europace/euaa268 Goldenberg, 2021, Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator, Heart Rhythm., 18, 404, 10.1016/j.hrthm.2020.11.025 Kutyifa, 2015, Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry), Circulation., 132, 1613, 10.1161/CIRCULATIONAHA.115.015677 Kutyifa, 2018, One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II registry), Pacing Clin. Electrophysiol., 41, 1307, 10.1111/pace.13448 Kutyifa, 2018, Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Europace, 20, f225 Odeneg, 2019, Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD registry, Eur. J. Cardiovasc. Nurs., 18, 75, 10.1177/1474515118790365 Röger, 2018, Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting, BMC Cardiovasc. Disord., 18, 52, 10.1186/s12872-018-0790-8 Rosenkaimer, 2020, The wearable cardioverter-defibrillator: experience in 153 patients and a long-term follow-up, J. Clin. Med., 9, 10.3390/jcm9030893 Sinha, 2021, The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital, J. Interv. Card. Electrophysiol., 62, 401, 10.1007/s10840-020-00898-5 Veltmann, 2021, Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry, Clin. Res. Cardiol., 110, 102, 10.1007/s00392-020-01657-2 Weiss, 2019, Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: results from the prospective multicenter CRED-registry, PLoS One, 14, 10.1371/journal.pone.0213261 Zoll Medical Corporation Fraser, 2020, Implementing the new European regulations on medical devices—clinical responsibilities for evidence-based practice: a report from the regulatory Affairs Committee of the European Society of cardiology, Eur. Heart J., 41, 2589, 10.1093/eurheartj/ehaa382 Wilkinson, 2020, The medical device regulation of the European Union intensifies focus on clinical benefits of devices, Ther. Innov. Regul. Sci., 54, 613, 10.1007/s43441-019-00094-2 Jarman, 2021, Neither protective nor harmonized: the crossborder regulation of medical devices in the EU, Health Econ. Policy Law., 16, 51, 10.1017/S1744133120000158 Centre of Evidence Based Medicine Victoria Israel, 2022, Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?, Clin. Res. Cardiol., 111, 1189, 10.1007/s00392-022-02003-4 Molloy, 2012, Interventions to enhance adherence to medications in patients with heart failure: a systematic review, Circ. Heart Fail., 5, 126, 10.1161/CIRCHEARTFAILURE.111.964569 Altman, 1995, Absence of evidence is not evidence of absence, Bmj., 311, 485, 10.1136/bmj.311.7003.485 McDonagh, 2021, 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J., 42, 3599, 10.1093/eurheartj/ehab368 Blue Cross Blue Shield Association Blockhaus, 2021, Wearable cardioverter-defibrillator used as a Telemonitoring system in a real-life heart failure unit setting, J. Clin. Med., 10 Rohrer, 2021, Multiparameter monitoring with a wearable cardioverter defibrillator, Sensors (Basel), 22, 10.3390/s22010022 Reiss, 2020, Telemedical concepts for heart failure patients treated with a wearable cardioverter defibrillator, Stud. Health Technol. Inform., 271, 93 van Ravenzwaaij, 2019, Bayes factors for superiority, non-inferiority, and equivalence designs, BMC Med. Res. Methodol., 19, 71, 10.1186/s12874-019-0699-7 Adelstein, 2018, The wearable cardioverter-defibrillation: an investment worth making or needing further investigation?, JACC Clin. Electrophysiol., 4, 240, 10.1016/j.jacep.2017.10.011 Usman, 2022, The need for increased pragmatism in cardiovascular clinical trials, Nat. Rev. Cardiol., 1 Sears, 2020, Collaborative care for the wearable cardioverter defibrillator patient: getting the patient and medical team "vested and active", J. Cardiovasc. Electrophysiol., 31, 2509, 10.1111/jce.14708 Younis, 2020, Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: how can we incorporate compliance into decision-making?, J. Cardiovasc. Electrophysiol., 31, 1019, 10.1111/jce.14403 Deneke, 2023 Boriani, 2021, Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: clinical and economic implications, Clin. Cardiol., 44, 1497, 10.1002/clc.23709 Botto, 2022, The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: economic and clinical implications from a health technology assessment perspective, Int. J. Cardiol., 356, 12, 10.1016/j.ijcard.2022.04.003 Raftery, 2020, 'Not clinically effective but cost-effective' - paradoxical conclusions in randomised controlled trials with 'doubly null' results: a cross-sectional study, BMJ Open, 10, 10.1136/bmjopen-2019-029596 Macleod, 2014, Biomedical research: increasing value, reducing waste, Lancet., 383, 101, 10.1016/S0140-6736(13)62329-6 Reeves BC, 2023, Chapter 24: Includ-ing non-randomized studies on intervention effects Saltzberg, 2012, Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator, J. Card. Fail., 18, 21, 10.1016/j.cardfail.2011.09.004 Skowasch, 2018, Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator, PLoS One, 13, 10.1371/journal.pone.0194496 Ellenbogen, 2017, Benefit of the wearable cardioverter-defibrillator in protecting patients after implantable-cardioverter defibrillator explant: results from the National Registry, JACC Clin. Electrophysiol., 3, 243, 10.1016/j.jacep.2016.09.002 Kaspar, 2018, Long-term use of the wearable cardioverter defibrillator in patients with explanted ICD, Int. J. Cardiol., 272, 179, 10.1016/j.ijcard.2018.08.017 Tscholl, 2021, Benefit of a wearable cardioverter defibrillator for detection and therapy of arrhythmias in patients with myocarditis, ESC Heart Fail., 8, 2428, 10.1002/ehf2.13353 Food and Drug Administration (FDA)